Northera approved for rare blood pressure condition

February 19, 2014

(HealthDay)—Northera (droxidopa) has been approved by the U.S. Food and Drug Administration to treat a rare, chronic condition characterized by a sudden drop in blood pressure when a person stands.

Neurogenic orthostatic hypotension (NOH) is most often associated with Parkinson's disease and other . Symptoms may include dizziness, lightheadedness, blurred vision, fatigue and fainting, the FDA said in a news release.

Granted accelerated approval to treat a rare condition, the drug will have a boxed label warning that it could cause an unhealthy rise in while a person is lying down. This potential side effect could lead to a stroke, the agency said, warning that Northera users should be monitored carefully.

Other less serious side effects could include headache, dizziness, nausea, and fatigue, the FDA said.

Northera is produced by Chelsea Therapeutics, based in Charlotte, N.C.

Explore further: Vimizim approved for rare childhood disorder

More information: The FDA has more about this approval.

Related Stories

Vimizim approved for rare childhood disorder

February 17, 2014

(HealthDay)—Vimizim (elosulfase alfa) has been approved by the U.S. Food and Drug Administration to treat a rare childhood disorder called Mucopolysaccharidosis Type IVA, also known as Morquio A syndrome.

Iclusig approved for rare leukemias

December 16, 2012

(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

Adempas approved to treat pulmonary hypertension

October 9, 2013

(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.

Opsumit approved for pulmonary arterial hypertension

October 23, 2013

(HealthDay)—Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a debilitating disease characterized by high blood pressure in the lung arteries.

Pomalyst approved for advanced multiple myeloma

February 9, 2013

(HealthDay)—Pomalyst (pomalidomide) has been approved by the U.S. Food and Drug Administration to treat cases of multiple myeloma that have not responded to other therapies.

Recommended for you

Universal flu vaccine designed by scientists

September 30, 2016

An international team of scientists have designed a new generation of universal flu vaccines to protect against future global pandemics that could kill millions.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.